Novo Nordisk A\/S (NYSE:NVO) is one of Jim Cramer\u2019s Hottest GLP-1 and Weight Loss Stock Picks<\/strong>.<\/p>\n Novo Nordisk A\/S (NYSE:NVO) is a key player in the weight loss drug industry. The firm made a splash earlier this year when it became the first to secure the FDA\u2019s approval for a weight loss drug pill. With the announcement occurring on December 22nd, Novo Nordisk A\/S (NYSE:NVO)\u2019s shares closed 7.3% higher on the 23rd. Since Cramer discussed the firm in April 2025, the shares are up by 44%, while they are down by 48% over the year. 2026 hasn\u2019t been a great year for Novo Nordisk A\/S (NYSE:NVO)\u2019s shares either, as they are down by 31% year-to-date. On February 23rd, the shares closed 16.4% lower as the firm reported that its next-generation weight loss drug, CagriSema, failed to match rival Eli Lilly\u2019s offering. The announcement marked another day of weak performance, as Novo Nordisk A\/S (NYSE:NVO)\u2019s stock had dipped by 19% between February 2nd and February 4th after the pharma company surprised investors through its guidance and commented that revenue and operating profit could dip between 5% and 13% each in 2026. Here\u2019s what Cramer said about the firm on Mad Money:<\/p>\n \u201cI do\u2026. It got low enough. When it hit 3.6% yield, it was low enough. Apparently, they\u2019re doing exactly what President Trump wants. I am a buyer at this point in Novo Nordisk, though of course I do like Eli Lilly more, but this stock has come down enough.\u201d<\/p>\n<\/blockquote>\n Jirsak\/Shutterstock.com<\/p>\n While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the\u00a0best short-term AI stock<\/strong>.<\/p>\n\n
<\/div>\n<\/div>